Cost-Effectiveness Analysis
SENSITIVITY
Incremental cost-effectiveness analysis was conducted based on differences in mean costs and QALYs between the 2 randomized groups. In the context of 1 group having higher mean costs and QALYs, incremental cost-effectiveness was estimated as the relevant intervention’s incremental cost per additional QALY. Judgments on the cost-effectiveness of interventions were performed by comparing the incremental cost-effectiveness ratio to the National Institute for Health and Care Excellence cost-effectiveness threshold range of £20 000 to £30 000 per QALY gained.Sensitivity analyses were performed to assess the robustness of the results. The analyses were conducted to evaluate the impact of key assumptions and uncertainties on the estimated incremental cost-effectiveness ratio and to test the validity of the findings. A probabilistic sensitivity analysis was considered to account for the joint uncertainty in all parameters simultaneously based on 1000 random samples from the parameter distributions, enabling the estimation of the probability of each intervention being cost-effective at a range of cost-effectiveness thresholds. A scenario analysis was also considered by varying the unit cost of implantable devices (CRT, CRT-D, and ICD only), covering values reported in 2 different sources (